Last reviewed · How we verify

Fundación Cardioinfantil Instituto de Cardiología — Portfolio Competitive Intelligence Brief

Fundación Cardioinfantil Instituto de Cardiología pipeline: 2 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

2 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Pharmaceutical fresh frozen plasma Pharmaceutical fresh frozen plasma marketed
Ringer lactate (RL) Ringer lactate (RL) marketed Crystalloid intravenous fluid Critical Care / Fluid Resuscitation

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Fayoum University Hospital · 1 shared drug class
  2. Federal University of Juiz de Fora · 1 shared drug class
  3. McGill University Health Centre/Research Institute of the McGill University Health Centre · 1 shared drug class
  4. Medical University of Vienna · 1 shared drug class
  5. Nationwide Children's Hospital · 1 shared drug class
  6. Rigshospitalet, Denmark · 1 shared drug class
  7. Scientific Institute San Raffaele · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Fundación Cardioinfantil Instituto de Cardiología:

Cite this brief

Drug Landscape (2026). Fundación Cardioinfantil Instituto de Cardiología — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/fundaci-n-cardioinfantil-instituto-de-cardiolog-a. Accessed 2026-05-18.

Related